NY-ESTÉE-LAUDER
11.5.2021 13:02:09 CEST | Business Wire | Press release
The Estée Lauder Companies Inc. (NYSE:EL) announced today that Meridith Webster will join the company in the newly-created role of Executive Vice President, Global Communications and Public Affairs , effective May 17, 2021. Meridith will report jointly to William P. Lauder, Executive Chairman, and Fabrizio Freda, President and Chief Executive Officer. She will also join The Estée Lauder Companies Inc.’s (“ELC”) Executive Leadership Team.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005345/en/
Meridith will succeed Alexandra (Alex) Trower as head of Global Communications and Maria Cristina (MC) González Noguera as head of Global Public Affairs. Her appointment follows the news that Alex has made the decision to retire in June after an esteemed career at the company, and that MC was recently tapped for the role of EVP and Chief Communications and Public Affairs Officer at Popular Inc., the Puerto Rico-based global financial services conglomerate.
“Our world-class Global Communications and Public Affairs teams have consistently advanced ahead of the curve against the backdrop of an increasingly complex and rapidly-changing global landscape,” said Fabrizio Freda . “Meridith’s appointment will continue to enable and enhance our delivery of thoughtful, effective communications to our valued global stakeholders as she leads these talented teams to new heights.”
“Meridith’s deep public and private sector experience, coupled with her core values and leadership style, make her uniquely suited to step into this role now,” said William P. Lauder . “I am so proud of the incredible work of our Global Communications and Public Affairs teams and I know they will be in great hands under Meridith’s leadership as she joins our ELC family.”
In this new role, Meridith will lead ELC’s global communications and public affairs strategic agendas to advance and protect its business interests and corporate reputation globally, and strengthen relationships to drive value for key stakeholders. She will serve as a strategic advisor to the ELC’s Executive Leadership Team, the Board of Directors and the Lauder Family on a variety of critical topics.
Meridith will oversee ELC’s Global Communications and Public Affairs teams, elevating the impact of these important functions across the business. She will lead the strategy and delivery of holistic, integrated global communications to advance ELC’s corporate reputation and winning business narrative, while building brand equity and strengthening the platforms that resonate with key audiences internally and externally. She will also lead the global public affairs and stakeholder engagement strategy to further advance ELC’s business goals, build reputation capital and proactively mitigate issues.
Meridith’s deep government experience includes tenures under multiple U.S. presidential administrations. Meridith joins ELC from the Biden White House, where she served as Special Assistant to the President and Chief of Staff to the Domestic Policy Council. At the Obama White House, she served as Senior Advisor to two White House Chiefs of Staff, Rahm Emanuel and Pete Rouse. She also served as Deputy Chief of Staff to Susan Rice, then the U.S. Ambassador to the United Nations. Meridith started her career working at the Clinton White House and the U.S. State Department before earning her J.D. Degree at Georgetown University Law Center.
Prior to serving in the Biden Administration, she served as Vox Media’s first-ever Chief Communications Officer, overseeing strategic and crisis communications and media relations across a growing modern media company, including editorial networks and advertising, studios, and podcasting. She also previously led the Public Affairs practice at Emerson Collective and served as Global Head of Public Affairs at Bloomberg L.P. and Bloomberg Philanthropies where she managed the expansion of the business and established public affairs and communications functions in Washington, New York and globally.
“I am thrilled to be joining The Estée Lauder Companies. Alex and MC each have done a terrific job leading the company’s Global Communications and Public Affairs functions and positioning these talented teams as strategic business partners,” said Meridith Webster . “It is an honor to step into this new role and I am excited to continue building on the successes of these teams in a rapidly-evolving space. I look forward to partnering with Fabrizio, William and the entire Executive Leadership Team to drive the overall success and continued growth of ELC.”
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, BECCA, Too Faced and Dr. Jart+.
ELC-C
ELC-L
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005345/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
